1. Home
  2. CINGW vs HII Comparison

CINGW vs HII Comparison

Compare CINGW & HII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • HII
  • Stock Information
  • Founded
  • CINGW N/A
  • HII 1886
  • Country
  • CINGW United States
  • HII United States
  • Employees
  • CINGW 13
  • HII N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • HII Marine Transportation
  • Sector
  • CINGW Health Care
  • HII Industrials
  • Exchange
  • CINGW Nasdaq
  • HII Nasdaq
  • Market Cap
  • CINGW N/A
  • HII N/A
  • IPO Year
  • CINGW 2021
  • HII N/A
  • Fundamental
  • Price
  • CINGW $0.06
  • HII $259.31
  • Analyst Decision
  • CINGW
  • HII Hold
  • Analyst Count
  • CINGW 0
  • HII 5
  • Target Price
  • CINGW N/A
  • HII $290.00
  • AVG Volume (30 Days)
  • CINGW N/A
  • HII 401.8K
  • Earning Date
  • CINGW N/A
  • HII 10-31-2024
  • Dividend Yield
  • CINGW N/A
  • HII 2.01%
  • EPS Growth
  • CINGW N/A
  • HII 44.93
  • EPS
  • CINGW N/A
  • HII 18.84
  • Revenue
  • CINGW N/A
  • HII $11,775,000,000.00
  • Revenue This Year
  • CINGW N/A
  • HII $3.79
  • Revenue Next Year
  • CINGW N/A
  • HII $3.63
  • P/E Ratio
  • CINGW N/A
  • HII $13.71
  • Revenue Growth
  • CINGW N/A
  • HII 8.04
  • 52 Week Low
  • CINGW N/A
  • HII $212.58
  • 52 Week High
  • CINGW N/A
  • HII $299.50
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • HII 46.37
  • Support Level
  • CINGW N/A
  • HII $247.26
  • Resistance Level
  • CINGW N/A
  • HII $259.79
  • Average True Range (ATR)
  • CINGW 0.00
  • HII 5.47
  • MACD
  • CINGW 0.00
  • HII -0.36
  • Stochastic Oscillator
  • CINGW 0.00
  • HII 59.42

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: